Efficacy of adding ginkgo biloba to ritalin in improving symptoms (attention,hyper activity and impulsivity)of children with ADHD(attention deficit hyper activity disorder)

Efficacy of adding ginkgo biloba to ritalin in improving symptoms (attention,hyper activity and impulsivity)of children with ADHD(attention deficit hyper activity disorder)in patients referring to noor hospital.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014111519958N1

Enrollment

Registered

2014-12-19

Start date

2014-11-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Disturbance of activity and attention

Interventions

Intervention 1: In control group tablet Ritalin 1mg/kg plus tablet placebo Ginkgo biloba for 4 weeks. Intervention 2: In intervention group tablet Ritalin 1mg/kg plus tablet Ginkgo biloba 80-120 mg/da

Treatment - Drugs

In control group tablet Ritalin 1mg/kg plus tablet placebo Ginkgo biloba for 4 weeks.

In intervention group tablet Ritalin 1mg/kg plus tablet Ginkgo biloba 80-120 mg/day(below 30 kg 80mg/day and more than 30 kg 120mg/day) for 4 weeks .

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1) age between 6-12 year 2) having attention attention deficit hyper activity disorder based on receiving DSM-IV-TR diagnostic criteria for ADHD (six criteria or more) 3)children global assesment CGAS less than 80 4)not using any psychiatric drugs at least 2 weeks before the research 5)signing informed written consents to participate in the study. Exclusion criteria 1)mental retardation(IQ<70) 2)bipolar type one disorder 3)psychotic disorder 4)pervasive developmental disorder 5)any combined conditions 6)presence of clinically significant chronic disease such as seizure organic brain disorders cardio vascular disease hyper or hypotention.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of attention deficit symptoms. Timepoint: at baseline and weeks 2 and 4 after the medication. Method of measurement: Attention Deficit Hyperactivity Disorder-Rating Scale-IV questionnaire.;Number of hyperactivity /impulsivity symptoms. Timepoint: at baseline and weeks 2 and 4 after the medication. Method of measurement: Attention Deficit Hyperactivity Disorder-Rating Scale-IV questionnaire.	—

Measure

Time frame

Number of attention deficit symptoms. Timepoint: at baseline and weeks 2 and 4 after the medication. Method of measurement: Attention Deficit Hyperactivity Disorder-Rating Scale-IV questionnaire.;Number of hyperactivity /impulsivity symptoms. Timepoint: at baseline and weeks 2 and 4 after the medication. Method of measurement: Attention Deficit Hyperactivity Disorder-Rating Scale-IV questionnaire.

—

Secondary

Measure	Time frame
Drug side effects. Timepoint: At baseline and weeks 2 and 4 after the medication. Method of measurement: Drug side effects check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrsa Radmanesh

Isfahan University of Medical Sciences

mehrsa.radmanesh@gmail.comshakibaei@med.mui.ac.ir+98 31 3222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 17, 2026